Mocht u de artikelen op kanker-actueel waarderen dan wilt u ons misschien ondersteunen met een donatie op

RABO 37.29.31.138 t.n.v. Stichting Gezondheid Actueel in Terneuzen.
Onze IBANcode is NL79 RABO 0372 9311 38
BIC/SWIFTCODE RABONNL2U

5 april 2019: lees ook dit artikel:

https://kanker-actueel.nl/hyperthermie-plus-voedingsprogramma-kytogeen-dieet-plus-hyperbare-zuurstoftherapie-aanvullend-op-chemo-geeft-uitstekende-resultaten-op-mediane-overall-overleving-42-maanden-bij-patienten-met-gevorderde-niet-kleincellige-longkanker.html

5 april 2019: Bron: Cureus. 2017 Jul; 9(7): e1445.

Vrouw van 29 jaar komt en blijft in complete remissie met aanvullend op chemo voor haar borstkanker stadium IV (triple negatief) persoonlijke voedingsadviezen, hyperthermie en hyperbare zuurstoftherapie.

Afgelopen week werd een studie gepubliceerd met meer dan uitstekende resultaten met een combinatie behandeling aanvullend op chemo van persoonlijke voedingsadviezen op basis van het kytogene dieet plus hyperthermie plus hyperbare zuurstof bij patienten met niet-kleincellige longkanker. Zie dit artikel

Ik vond in pubmed een mooie case studie met diezelfde aanpak bij een vrouw van 29 jaar met triple negatieve borstkanker die binnen een half jaar in een complete remissie kwam en bleef. En niet onbelangrijk met goede kwaliteit van leven en heel acceptabele bijwerkingen.

Na het bereiken van de complete remissie stellen de onderzoekers dat de aanwezigheid van microscopische tumorcellen niet kan worden uitgesloten. Daarom hebben zij besloten door te gaan met hetzelfde behandelingsregime van MSCT, KD, HT en HBOT tot een volledig jaar na implementatie, waarbij ervoor wordt gezorgd dat de cumulatieve cardiale toxiciteitsdosis voor doxorubicine, die deel uitmaakt van haar MSCT-regime, niet wordt overschreden. Tijdens deze periode zal de patiënt elke drie maanden een follow-upscan ondergaan.

Hier het verloop van de vrouw haar ziekte en behandelingen:

Table 2

Summary showing timeline of events

Abbreviations: CT, computed tomography; FDG, fluorodeoxyglucose; HBOT, hyperbaric oxygen therapy; HT, hyperthermia; KD, ketogenic diet; MRI, magnetic resonance imaging; MSCT, metabolically supported chemotherapy; PET, positron emission tomography; TNBC, triple-negative breast cancer.

Date	Event
December 2015	Lump in left breast detected with physical examination.
December 2015 - August 2016	No further imaging is done.
August 2016	Admitted to Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey where MRI revealed a 75 mm x 75 mm x 65 mm left breast mass with multiple lymphadenomegaly in the left axilla.
August 2016	Tru-cut biopsy confirmed a diagnosis of stage IV TNBC.
October 2016	Admitted to ChemoThermia Oncology Center, Istanbul, Turkey where whole body (18F)-FDG-PET-CT revealed a 77 x 55 mm primary tumor in her left breast together with multiple left pectoral and axillary lymph nodes, multiple wide spread liver masses and an upper left nodular abdominal lesion.
October 2016 - February 2017	Received a treatment protocol consisting of MSCT, KD, HT and HBOT. She received MSCT on the first and eighth day of a 21-day cycle and following each MSCT session she received local HT and HBOT together with being encouraged to consume a KD.
February 2017	Whole body (18F)-FDG-PET-CT demonstrated complete therapeutic response with no malignant FDG uptake following 12 sessions of MSCT, HT, and HBOT together with KD therapy.
February 2017 – April 2017	Continued to receive the same treatment protocol for an additional six sessions.
April 2017	Underwent mastectomy of the left breast with axillary dissection which revealed a pathological complete response.

Open in a separate window

After achieving this outcome, even though there is no evidence of disease, the presence of microscopic disease cannot be excluded. Consequently, we have decided to continue with the same treatment regimen of MSCT, KD, HT and HBOT to one full year from implementation, taking care not to exceed the cumulative cardiac toxicity dose for doxorubicin, which is part of her MSCT regimen. During this period, the patient will undergo follow-up scans every three months.

Ik ga het maar niet vertalen verder en uitleggen maar leest u het volledige studieverslag:

Efficacy of Metabolically Supported Chemotherapy Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy for Stage IV Triple-Negative Breast Cancer

Hier het abstract van deze casestudie en referentielijst waarin nog meer studies met deze aanpak worden vermeld.

Cureus. 2017 Jul; 9(7): e1445.

Published online 2017 Jul 7. doi: 10.7759/cureus.1445

PMCID: PMC5589510

PMID: 28924531

Efficacy of Metabolically Supported Chemotherapy Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy for Stage IV Triple-Negative Breast Cancer

Monitoring Editor: Alexander Muacevic and John R Adler

Mehmet Salih İyikesici,¹ Abdul Kadir Slocum,² Ayshe Slocum,² Ferhan Bulent Berkarda,² Miriam Kalamian,³ and Thomas N Seyfried⁴

Author information Article notes Copyright and License information Disclaimer

Abstract

Triple-negative breast cancer (TNBC) is more aggressive and metastatic than other breast cancer types. Cytotoxic chemotherapy is presently the predominant systemic therapy for TNBC patients. This case report highlights the influence of metabolically supported chemotherapy (MSCT), ketogenic diet (KD), hyperthermia (HT), and hyperbaric oxygen therapy (HBOT) in an overweight 29-year-old woman with stage IV (T4N3M1) triple-negative invasive ductal carcinoma of the breast. The patient presented with an observable mass in her left breast detected during a physical examination in December 2015. Magnetic resonance imaging revealed a Breast Imaging Reporting and Data System Category 5 tumor and multiple lymphadenomegaly in the left axilla. A Tru-Cut biopsy led to the diagnosis of a triple-negative nuclear grade 2 invasive ductal carcinoma. The patient was admitted to ChemoThermia Oncology Center, Istanbul, Turkey in October 2016, and a whole body (18F)-fluorodeoxyglucose (FDG)-positron emission tomography-computed tomography (PET-CT) scan revealed a 77 mm x 55 mm primary tumor in her left breast, multiple left pectoral and axillary lymph nodes, multiple widespread liver masses, and an upper left nodular abdominal lesion. The patient received a treatment protocol consisting of MSCT, KD, HT, and HBOT. A follow-up whole body 18F-FDG PET-CT scan in February 2017 showed a complete therapeutic response with no evidence of abnormal FDG uptake. The patient continued to receive this treatment protocol and in April 2017 underwent a mastectomy, which revealed a complete pathological response consistent with the response indicated by her PET-CT imaging. This single case study presents evidence of a complete clinical, radiological, and pathological response following a six-month treatment period using a combination of MSCT and a novel metabolic therapy in a patient with stage IV TNBC.

Referentielijst:

The authors have declared that no competing interests exist.

Go to:

Human Ethics

Consent was obtained by all participants in this study

Go to:

References

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Ferlay J, Soerjomataram I, Dikshit R, et al. Int J Cancer. 2015;136:359–386. [PubMed] [Google Scholar]

2. The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer. Castrellon AB, Pidhorecky I, Valero V, et al. Oncol Rev. 2017;11:324. [PMC free article] [PubMed] [Google Scholar]

3. On the origin of cancer cells. Warburg O. Science. 1956;123:309–314. [PubMed] [Google Scholar]

4. Complete response of locally advanced (stage III) rectal cancer to metabolically supported chemoradiotherapy with hyperthermia. Iyikesici MS, Slocum A, Turkmen E, et al. Int J Cancer Res Mol Mech. 2016;2:1–4. [Google Scholar]

5. Long-term outcomes of the treatment of unresectable (stage III - IV) ductal pancreatic adenocarcinoma using metabolically supported chemotherapy (MSCT): a retrospective study. Iyikesici MS, Slocum A, Turkmen E, et al. http://pancreas.imedpub.com/longterm-outcomes-of-the-treatment-of-unresectable-stage-iii--ivductal-pancreatic-adenocarcinoma-using-metabolically-supported-chemotherapy-msct-a-retrospective-study.pdf J Pancreas. 2015;17:36–41. [Google Scholar]

6. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case report. Zuccoli G, Marcello N, Pisanello A, et al. Nutr Metab (Lond) 2010;7:33. [PMC free article] [PubMed] [Google Scholar]

7. Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for non-small cell lung cancer with multiple pulmonary metastases: preliminary results. Ohguri T, Imada H, Narisada H, et al. Int J Hyperthermia. 2009;25:160–167. [PubMed] [Google Scholar]

8. Non-toxic metabolic management of metastatic cancer in VM mice: novel combination of ketogenic diet, ketone supplementation, and hyperbaric oxygen therapy. Poff AM, Ward N, Seyfried TN, et al. PLoS One. 2015;10:127407. [PMC free article] [PubMed] [Google Scholar]

9. Press-pulse: a novel therapeutic strategy for the metabolic management of cancer. Seyfried TN, Yu G, Maroon J, et al. Nutr Metab (Lond) 2017;14:19. [PMC free article] [PubMed] [Google Scholar]

10. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Cortazar P, Zhang L, Untch M, et al. Lancet. 2014;384:164–172. [PubMed] [Google Scholar]

Articles from Cureus are provided here courtesy of Cureus Inc

borstkanker triple negatief, hyperthermie, hyperbare zuurstoftherapie, chemo, kytogeen dieet, persoonljke voedingsadviezen